Other Income & Expense

Change in AP

Vertex Pharmaceuticals Change in AP remained flat by 0.0% to $9.20M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 25.7%, from $12.38M to $9.20M. Over 2 years (FY 2023 to FY 2025), Change in AP shows a downward trend with a -13.1% CAGR.

Analysis

StatementIncome Statement
SectionOther Income & Expense
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025

How to read this metric

An increase suggests the company is extending payment terms to preserve cash, while a decrease indicates faster settlement of obligations.

Detailed definition

Measures the net change in amounts owed to suppliers for goods and services received. It serves as an indicator of the c...

Peer comparison

Standard working capital metric used across all industries.

Metric ID: is_ms_change_in_accounts_payable

Historical Data

3 years
 FY'23FY'24FY'25
Value$48.70M$49.50M$36.80M
YoY Change—+1.6%-25.7%
Range$36.80M – $49.50M
CAGR-13.1%
Avg YoY Growth-12.0%
Median YoY Growth-12.0%

Frequently Asked Questions

What is Vertex Pharmaceuticals's change in ap?
Vertex Pharmaceuticals (VRTX) reported change in ap of $9.20M in Q4 2025.
How has Vertex Pharmaceuticals's change in ap changed year-over-year?
Vertex Pharmaceuticals's change in ap decreased by 25.7% year-over-year, from $12.38M to $9.20M.
What is the long-term trend for Vertex Pharmaceuticals's change in ap?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's change in ap has grown at a -13.1% compound annual growth rate (CAGR), from $48.70M to $36.80M.
What does change in ap mean?
The net change in the balance of money owed to suppliers during the period.